Dr Kantarjian on the Predictive Value of Early Responses to Ponatinib in CP-CML

Hagop M. Kantarjian, MD, discusses the predictive value of early landmark cytogenetic or molecular responses to ponatinib in heavily pretreated patients with chronic-phase chronic myeloid leukemia.

Related Keywords

Texas ,United States ,Hagopm Kantarjian , ,Department Of Leukemia ,University Of Texas Md Anderson Cancer Center ,Samsung Distinguished Leukemia Chair ,Cancer Medicine ,Cancer Center ,Soho Annual Meeting ,Soho 2023 ,Cp Cml ,Ncml ,Ponatinib ,